A New History of Vaccines for Infectious Diseases: Immunization - Chance and Necessity. This item is unavailable.A New History of Vaccines for Infectious Diseases: Immunization - Chance and Necessity

A New History of Vaccines for Infectious Diseases: Immunization - Chance and Necessity covers the developments of vaccines and how they have obliterated many fatal diseases and infections over time. The book treads a neutral path but does not avoid discussion. As uncertainty in the outcome of vaccination can only be determined by experiment, the path to vaccine development has been scientifically complex because the immune system and the manner in which humans respond to infection is variable and complex.  Finally, the book describes the risks and benefits of vaccines in a visibly objective manner.

• 2023 PROSE Awards - Winner: Finalist: History of Science, Medicine, and Technology: Association of American Publishers
• Gives an objective description of the science behind vaccine discovery
• Presents awareness and discussions on controversies, both past and present
• Provides historical context to the scientific aspects of immunization, including what worked, what didn't, and why
• Written by a scientist with no ‘vested interest’ in vaccine development
• Clears up many misunderstandings for today’s vaccination policies

Anthony Robert Rees, educated at the University of Oxford (MSc, MA, DPhil), has had a distinguished academic and research career spanning over 30 years in receptor biology and molecular immunology. He served as a Lecturer in Molecular Biophysics at Oxford (1980-90) before becoming Professor of Biochemistry and Head of the School of Biology & Biochemistry at the University of Bath (1990-97). He was honored with an Emeritus Professorship in 2003 and a Doctor of Science Honoris Causa in 2009 by the University of Bath. Rees co-founded the Oxford University spin-out, Oxford Molecular plc, in 1989, which floated on the LSE in 1994. He held senior executive roles in French and Swedish biotech companies and was a founding board member of the Austrian antibody biotech company F-star. An expert in antibody repertoire theory, he is a consultant in immunology and a member of the American Association for the History of Medicine.